Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized study of PegBin in hydroxyurea-resistant or -intolerant high-risk essential thrombocythemia
CTR20242549Phase 2Active
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Sep 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in thrombocythemia, sponsored by Xiamen Tebao Biological Engineering Co., Ltd.. Started Sep 2024; status: active.
02
Drugs
peginterferon alfa-2b
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on CTR20242549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242549.